ClinicalTrials.gg
CompletedNCT00880308Updated Dec 19, 2020

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of LDE225 in Advanced Solid Tumor Cancers, Medulloblastoma and Basal Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.

Enrollment
30th of 215
103 · median 30
Started
2009
with 9 others
Phase 1
115 of 245
10 open now
Registered
102nd of 245
by date
Lead sponsor
6 of 245
Novartis Pharmaceuticals

Among the 245 studies in Medulloblastoma with a site in United States, this one is the 30th largest by enrollment of the 215 interventional ones that give a count, is one of 10 that started in 2009, is one of 115 in phase 1, and was the 102nd registered.

Medulloblastoma

317 studies on the registry are indexed under Medulloblastoma; 51 are open to participants now.

Browse Medulloblastoma studies →

Open to participants now

26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 31 (84%) stop at 75 or younger; 34 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Medulloblastoma with a site in United States, or all of them as a file.
02

Study summary

This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.

03

Conditions studied

  • Advanced Solid Tumor Cancers
  • Medulloblastoma
  • Basal Cell Carcinoma

Keywords

  • Advanced tumors
  • hedgehog
  • smoothened inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of advanced solid tumor (including •medulloblastoma and basal cell carcinoma)
  • blood work criteria

Exclusion criteria

Exclusion Criteria:

  • patients with history of brain tumor (except recurrent medulloblastoma) or
  • positive , or C
  • impaired intestinal function
  • impaired heart function
  • pregnant or breast-feeding women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    LDE225

    Drug: LDE225

Interventions

06

What researchers measure

Primary outcomes

  1. determine maximum tolerated dose of single agent LDE225

    Time frame: 28 day cycles

Secondary outcomes

  1. characterize safety and tolerability

    Time frame: 28 day cycles

  2. characterize pharmacokinetics (PK) of single and repeated doses of LDE225

    Time frame: 28 day cycles

  3. assess preliminary anti-tumor activity

    Time frame: every other 28-day cycle

07

Study locations

5 sites
  • University of Pittsburgh Medical Center SC
    Pittsburgh, Pennsylvania 15213, United States
  • Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Zürich, 8091, Switzerland
  • Novartis Investigative Site
    Leicester, LE1 5WW, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2009
First posted
Apr 13, 2009
Start
Mar 2009
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00880308
Responsible party
Sponsor
First posted
Apr 13, 2009
Start date
Mar 2009
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Dec 19, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion